In April 2026, XellSmart officially launches its multicenter Phase II registrational clinical trial of the "Clinical-Grade, Allogeneic, Off-the-Shelf, iPSC-Derived, Dopaminergic Neural Progenitor Cell ...
Parkinson’s disease (PD) is entering a pivotal phase. For decades, treatment has centred on dopamine replacement to manage ...
Solengepras showed evidence of potential benefit in functional and non-motor symptoms versus placebo as measured by MDS-UPRDS Parts I, II, NMSS, and ESS, consistent with its novel non-dopaminergic ...
Please provide your email address to receive an email when new articles are posted on . There is a need to look past dopaminergic therapy and target inflammation for disease modification. Chronic ...
Solengepras, a once-daily, oral, non-dopaminergic GPR6 inhibitor, demonstrated meaningful reductions in daily OFF time and ...
While the prevalence of Parkinson’s disease (PD) has doubled over the past 20 years, the treatment paradigm has remained largely unchanged. In fact, for more than fifty years, the management of PD has ...
Two independent clinical trials demonstrate the safety of stem cell therapies for Parkinson's disease. The papers, published in Nature this week, investigate the use of cells derived from human ...
A new organoid model of the dopaminergic system sheds lights on its intricate functionality and potential implications for Parkinson's disease. The model replicates the dopaminergic system's structure ...
New evidence suggests that trapping iron in unusable forms may starve vulnerable neurons, challenging decades of thinking about iron toxicity in Parkinson’s disease and opening new therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results